Journal of Clinical Oncology
Articles in this Issue
Initial biopsy results of the PATROL study: Prostate screening for people with inherited risk of developing aggressive prostate cancer.
426 Background: Germline pathogenic variants (gPV) in prostate cancer (PrCa) risk genes are associated with aggressive disease and worse outcomes. However...
Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.
70 Background: 177-Lutetium Prostate-specific membrane antigen (Lu-PSMA) therapy is under current scientific investigation and aims to become an establish...
Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
TPS288 Background: Resistance to androgen receptor (AR) pathway inhibitors (ARPI; e.g., abiraterone, enzalutamide) in metastatic castration-resistant pros...
Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.
820 Background: Prognostication of urothelial bladder carcinoma relies on clinicopathologic factors including histology, TNM stage and genomic profiles. T...
Racial disparities in incidence-based mortality and survival outcomes in testicular cancer in adolescent and young adults.
650 Background: Testicular cancer is the most common malignancy in males aged 15-35, with increasing incidence worldwide. Despite overall high survival ra...
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).
TPS279 Background: PARP inhibitors (PARPi) in combination with androgen receptor pathway inhibitors (ARPIs) are approved for treatment of metastatic castr...
A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC).
557 Background: The efficacy of targeted therapy alone in the treatment of advanced nccRCC remains unsatisfactory, but its combination with immunotherapy...
Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.
637 Background: Primary RP GCT represents a rare subset of extragonadal GCTs. While front-line therapy remains similar to gonadal GCT, there is limited da...
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).
22 Background: Metastases directed therapy (MDT) in metachronous hormone sensitive prostate cancer (mHSPS) patients has been shown to delay systemic thera...
Application of ML models to predict postoperative outcomes in renal cell carcinoma.
463 Background: Accurately predicting postoperative outcomes, such as major and minor complications, readmissions, and mortality, enables personalized pre...
A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk.
TPS895 Background: Current studies indicate that the combination of Disitamab Vedotin and PD-1 inhibitors can enhance the efficacy of systemic therapy in...
A phase I/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS).
TPS431 Background: The recent LuTectomy trial suggested that intra-venous [177Lu]Lu-PSMA-617 prior to surgery in men with high-risk localised or locally a...
PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting agent.
856 Background: FX-909, a PPARG inverse agonist, is being evaluated in a first-in-human, dose escalation and expansion study in patients with advanced uro...
Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker.
364 Background: Over the past decade, multiple biomarkers have been developed and validated to improve precision of prostate cancer prognosis estimation....
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.
662 Background: Activating alterations in FGFR3 (most commonly S249C) occur in 15-...
PSMA PET vs. pelvic MRI in biochemically recurrent prostate cancer.
40 Background: After primary definitive therapy of localized prostate cancer with either radical prostatectomy or radiation therapy, up to 50% of patients...
Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.
540 Background: Ipilimumab (IPI) and nivolumab (NIVO) are standard first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). Th...
Mass cytometry-based deep immune cell profiling of metastatic clear cell renal cell carcinoma patients refractory to combined immune checkpoint and tyrosine kinase inhibitor therapy.
576 Background: Combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) improved outcomes for patients with metastatic cl...
Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
841 Background: According to the current guidelines, upper tract urothelial carcinoma (UTUC), which encroaches beyond the muscularis propria but does not...
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
571 Background: Immune checkpoint inhibitors (ICI) have led to remarkable, long-lasting responses in a subset of patients with metastatic renal cell carci...
OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy.
TPS286 Background: The androgen receptor (AR) plays a pivotal role in prostate cancer pathogenesis, even after progression on androgen-directed therapies...
Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC).
845 Background: CAUBC (metastatic and surgically incurable advanced UBC) is a challenging with significant need for improvement in systemic therapies. We...
CORE-008: A phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.
TPS901 Background: Treatment for patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) consists of Transurethral Resection of Bladder Tumo...
Evaluating molecular alteration profiles to distinguish intraductal carcinoma of the prostate.
407 Background: Intraductal carcinoma of the prostate (IDC-P) is an intra-acinar and/or intraductal neoplastic epithelial proliferation that is a distinct...
Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.
423 Background: Surgery is a process that heavily relies on complex visual information. Many AI-based surgical teaching and assistance applications have e...